{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:01:20Z","timestamp":1791961280621,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jaad.2025.08.081","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T14:54:06Z","timestamp":1756565646000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study"],"prefix":"10.1016","volume":"94","author":[{"given":"Matthew","family":"Zirwas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Joseph F.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alim R.","family":"Devani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Halden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuTzu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haq","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda F.","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10470","key":"10.1016\/j.jaad.2025.08.081_bib1","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(24)01810-5","article-title":"Hand eczema","volume":"404","author":"Weidinger","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.081_bib2","first-page":"e1","article-title":"Guidelines for diagnosis, prevention and treatment of hand eczema","volume":"13","author":"Diepgen","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.jaad.2025.08.081_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/cod.13804","article-title":"Prevalence, incidence, and severity of hand eczema in the general population - a systematic review and meta-analysis","volume":"84","author":"Quaade","year":"2021","journal-title":"Contact Dermatitis"},{"issue":"6","key":"10.1016\/j.jaad.2025.08.081_bib4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/bjd\/ljaf020","article-title":"Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60,000 respondents in the general population in Canada, France, Germany, Italy, Spain, and the United Kingdom","volume":"192","author":"Apfelbacher","year":"2025","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2025.08.081_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jdv.16061","article-title":"Hand eczema: epidemiology, prognosis and prevention","volume":"34","author":"Agner","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.081_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-018-8685-0","article-title":"The unique molecular signatures of contact dermatitis and implications for treatment","volume":"56","author":"Leonard","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2025.08.081_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/1744666X.2023.2174526","article-title":"Topical and systemic JAK inhibitors in hand eczema - a narrative review","volume":"19","author":"Zalewski","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2025.08.081_bib8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/ijms25010362","article-title":"New perspectives in the management of chronic hand eczema: lessons from pathogenesis","volume":"25","author":"Tancredi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jaad.2025.08.081_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12840","article-title":"Current and emerging therapies for hand eczema","volume":"32","author":"Lee","year":"2019","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2025.08.081_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/cod.14035","article-title":"Guidelines for diagnosis, prevention, and treatment of hand eczema","volume":"86","author":"Thyssen","year":"2022","journal-title":"Contact Dermatitis"},{"issue":"3","key":"10.1016\/j.jaad.2025.08.081_bib11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1523-1747.2003.12053.x","article-title":"Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities","volume":"120","author":"Kao","year":"2003","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.08.081_bib12","first-page":"1198","article-title":"A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy","volume":"13","author":"Fowler","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.08.081_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4155\/cli.14.58","article-title":"Alitretinoin for the treatment of chronic hand eczema: clinical rationale","volume":"4","author":"Shi","year":"2014","journal-title":"Clin Investig (Lond)"},{"key":"10.1016\/j.jaad.2025.08.081_bib14","series-title":"Full Prescribing Information","article-title":"ANZUPGO\u00ae (Delgocitinib)","year":"2025"},{"key":"10.1016\/j.jaad.2025.08.081_bib15","series-title":"Summary of Product Characteristics","article-title":"ANZUPGO\u00ae (Delgocitinib)","year":"2024"},{"issue":"7","key":"10.1016\/j.jaad.2025.08.081_bib16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/pharmaceutics13071044","article-title":"Developing a JAK inhibitor for targeted local delivery: ruxolitinib cream","volume":"13","author":"Smith","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jaad.2025.08.081_bib17","series-title":"Full Prescribing Information","article-title":"Opzelura\u00ae (Ruxolitinib Cream)","year":"2024"},{"key":"10.1016\/j.jaad.2025.08.081_bib18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/jvc2.381","article-title":"Topical ruxolitinib 1.5% (JAK1\/JAK2 inhibitor) improves clinical and patient-reported outcomes in moderate to severe chronic hand dermatitis: data from a small open-label trial","volume":"3","author":"Smith","year":"2024","journal-title":"JEADV Clin Pract"},{"issue":"2","key":"10.1016\/j.jaad.2025.08.081_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2133.2004.06305.x","article-title":"The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. a study of inter- and intraobserver reliability","volume":"152","author":"Held","year":"2005","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.08.081_bib20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"10.1016\/j.jaad.2025.08.081_bib21","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2025.08.081_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.08.081_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2018.02.012","article-title":"JAK\/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease","volume":"120","author":"Howell","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10451","key":"10.1016\/j.jaad.2025.08.081_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","article-title":"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials","volume":"404","author":"Bissonnette","year":"2024","journal-title":"Lancet"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225027173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225027173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:24:18Z","timestamp":1773134658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225027173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0190962225027173"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.08.081","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.08.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}